What is Being Tested in the Leukemia Panel
A leukemia/lymphoma flow cytometry immunophenotyping panel evaluates specific cell surface and intracellular markers (CD antigens) to determine the lineage, maturity, and clonality of abnormal blood cells, enabling accurate diagnosis and classification of hematologic malignancies.
Core Markers for Acute Leukemia Diagnosis
The most comprehensive acute leukemia panels include these top-ranked markers based on current guidelines 1:
Essential Markers (Present in >80% of panels):
- CD19 - B-cell lineage marker (100% inclusion)
- Cytoplasmic CD3 (cCD3) - T-cell lineage marker
- CD34 - Immaturity/blast marker
- CD10 - B-cell maturation and ALL subtyping
- Cytoplasmic MPO (cMPO) - Myeloid lineage marker
- CD45 - Pan-leukocyte marker for gating
- Cytoplasmic CD79a (cCD79a) - B-cell lineage confirmation
- CD7 - T-cell marker
- HLA-DR - Activation/maturation marker
Additional Discriminatory Markers:
- CD13 - Myeloid differentiation (particularly useful in limited panels) 1
- Surface CD3 (sCD3) - Mature T-cell marker
- TdT (Terminal deoxynucleotidyl transferase) - Immaturity marker 2, 3
The EuroFlow™ Acute Leukemia Orientation Tube (ALOT), which serves as a validated screening panel, contains CD19, cCD3, CD34, cMPO, CD45, cCD79a, CD7, and sCD3 1. When used as a definitive limited panel rather than screening tool, adding CD10 and CD13 significantly improves diagnostic accuracy for ALL subtyping and myeloid differentiation respectively 1.
Lymphoproliferative Disorder/CLL Panel
For chronic lymphocytic leukemia and lymphoproliferative disorders, the consensus-based panel includes 8 core markers 1:
Required Markers:
- CD19 - B-cell marker (100% inclusion)
- CD5 - Aberrant T-cell marker on B-cells (92% inclusion)
- Kappa/Lambda - Light chain clonality assessment (83% inclusion)
- CD20 - B-cell marker (75% inclusion)
- CD23 - CLL-specific marker (67% inclusion)
Recommended Additional Markers:
- CD10 - Differentiates follicular lymphoma and DLBCL from CLL (42% inclusion) 1
- CD45 - Improves gating accuracy and reduces operator error (33% inclusion) 1
- CD22 or FMC-7 - Alternative B-cell markers
The addition of CD10 and CD45 to traditional CLL panels is increasingly recommended because CD45 reduces technical errors in scatter plot analysis, while CD10 improves classification of non-CLL lymphoproliferative disorders like follicular lymphoma and diffuse large B-cell lymphoma 1.
Advanced Markers for Minimal Residual Disease (MRD)
For post-treatment monitoring, newer markers show superior performance 4:
Excellent MRD Markers (>85% baseline expression, >75% post-therapy retention):
- CD97
- CD73
- CD86
- CD58
Highly Promising MRD Markers (>50% baseline, >85% post-therapy retention):
- CD81
- CD49f (notably can appear as new LAIP post-therapy even if absent at baseline)
T/NK-Cell Leukemia/Lymphoma Panel
For T/NK-cell malignancies, a standardized 13-antibody panel includes 5:
- T-cell markers: CD2, CD3, CD5, CD7, CD4, CD8
- NK-cell markers: CD56, CD57
- TRBC1 (T-cell receptor β-chain constant region 1) - critical for detecting clonal T-cell populations
- Additional markers: CD11c, CD34
Clinical Context and Pitfalls
Critical caveat: The panel composition depends heavily on available resources and clinical question 1. In resource-limited settings, even basic lineage determination (lymphoid vs. myeloid) using morphology and cytochemistry alone achieves only 42% diagnostic accuracy 1, making flow cytometry essential for adequate patient outcomes.
Common pitfall: Distinguishing screening panels from definitive limited panels. Screening panels (like EuroFlow™ ALOT) are designed to guide further testing, while limited panels must provide final diagnostic information when combined with morphology 1. Using a screening panel as a definitive test will miss critical diagnostic information.
Atypical immunophenotypes occur in approximately 20% of CLL cases 6, most commonly showing increased CD20 (32%), negative CD43 (32%), negative ROR1 (30%), or increased surface light chain (21%). These atypical cases more frequently harbor trisomy 12 (58.5% vs. 20.7%) and mutations in BIRC3, KRAS, NRAS, KMT2D, and SMARCA4 6.